Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer

Trial ID or NCT#

NCT05243524

Status

not recruiting iconNOT RECRUITING

Purpose

Phase 2, single arm, study to assess the efficacy and safety of maveropepimut-S (MVP-S) and low-dose cyclophosphamide (CPA) in subjects with recurrent, platinum resistant ovarian cancer.

Official Title

Phase 2b Single Arm Study of Maveropepimut-S and Low-Dose Cyclophosphamide in Subjects With Platinum-Resistant, Epithelial Ovarian Cancer.

Eligibility Criteria

Sexes Eligible for Study: FEMALE
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Oliver Dorigo
Oliver Dorigo
Gynecologic oncologist, Medical oncologist, Gynecologic oncologist
Mary Lake Polan Professor

Contact us to find out if this trial is right for you.

Contact

Alaina Poe
650-724-3308

View on ClinicalTrials.gov